Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 8/20 | 0.78 |
| ▸ | RAF1 | P04049 | 3/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CSF1R | P07333 | 12/20 | 0.51 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.51 |
| ▸ | ARAF | P10398 | 1/20 | 0.51 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.51 |
| ▸ | ERN1 | O75460 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | TEK | Q02763 | 1/20 | 0.48 |
| ▸ | MELK | Q14680 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9930824 | 0.89 | BRAF (0.75) | BRAFRAF1CYP2C9CSF1RDDR2 | |
| SCHEMBL10250937 | 0.89 | BRAF (0.72) | BRAFRAF1CYP2C9CSF1RDDR2 | |
| SCHEMBL10250940 | 0.88 | BRAF (0.73) | BRAFRAF1CYP2C9CSF1RDDR2 | |
| SCHEMBL10251228 | 0.88 | BRAF (1.00) | BRAFRAF1CYP2C9CSF1RDDR2 | |
| SCHEMBL10251060 | 0.86 | BRAF (1.00) | BRAFRAF1CYP2C9CSF1RDDR2 | |
| SCHEMBL10285819 | 0.85 | BRAF (0.69) | BRAFRAF1CYP2C9CSF1RDDR2 | |
| SCHEMBL12826338 | 0.84 | BRAF (0.80) | BRAFRAF1CYP2C9ERN1 | |
| SCHEMBL10251561 | 0.84 | BRAF (0.73) | BRAFRAF1CYP2C9CSF1RDDR2 | |
| SCHEMBL9930449 | 0.84 | BRAF (0.73) | BRAFRAF1CYP2C9CSF1RDDR2 | |
| SCHEMBL10254607 | 0.84 | BRAF (0.81) | BRAFRAF1CYP2C9CSF1RDDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011025940-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | BRAF 1/4885RAF1 2/4885CYP2C9 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.